NDA 218213 · Bristol
Augtyro
Repotrectinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Nov 15, 2023: To treat ROS1-positive non-small cell lung cancer
Last checked: Nov 19, 2026Latest source record: Jun 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Nov 15, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
1 Phase 3, 6 recruiting
FAERS reports
274
174 serious, 36 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 13, 2024.
AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion and • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) 1.1 ROS1 -Positive Non-Small Cell Lung Cancer AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration (2.1) ] . 1.2 NTRK Gene Fusion-Positive Solid Tumors AUGTYRO is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion [see Dosage and Administration ( 2.1 )] , • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.2 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. Fusion proteins that include ROS1 or TRK domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation. Repotrectinib exhibited anti-tumor activity in cultured cells expressing ROS1 fusions and mutations including SDC4-ROS1, SDC4-ROS1 G2032R , CD74-ROS1, CD74-ROS1 G2032R , CD74-ROS1 D2033N , and CD74-ROS1 L2026M . Repotrectinib also inhibited cell...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 13, 2024 Supplement 1 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Nov 15, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLabelLetter
2 products under this application
- AUGTYRO · REPOTRECTINIB 160MG · CAPSULE, ORAL · Prescription
- AUGTYRO · REPOTRECTINIB 40MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Repotrectinib" as an intervention, any sponsor and status, largest first.
Turning Point Therapeutics, Inc.Industry
NCT03093116 · 500 participants (planned) · Start Mar 7, 2017 · Primary completion Feb 29, 2028
Drug: Oral repotrectinib (TPX-0005) · For: Locally Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Duarte, California; Glendale, California; La Jolla, California · 165 sites in all
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06140836 · 190 participants (planned) · Start Dec 21, 2023 · Primary completion Feb 16, 2027
Drug: Repotrectinib; Crizotinib · For: Carcinoma, Non-Small-Cell Lung
Sites: Boston, Massachusetts; Mineola, New York; New York, New York · 120 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05004116 · 77 participants (planned) · Start Aug 9, 2021 · Primary completion Aug 2028
Drug: Repotrectinib; Irinotecan and temozolomide · For: Advanced Cancer; Metastatic Solid Tumor
Sites: New York, New York
Turning Point Therapeutics, Inc.Industry
NCT04094610 · 75 participants (planned) · Start Mar 12, 2020 · Primary completion Sep 30, 2026
Drug: Oral repotrectinib (TPX-0005) · For: Locally Advanced Solid Tumors; Metastatic Solid Tumors; Lymphoma and 1 more
Sites: Los Angeles, California; Aurora, Colorado; Orlando, Florida · 68 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06493409 · 32 participants · Start Aug 26, 2024 · Primary completion Dec 7, 2024
Drug: Repotrectinib; Voriconazole and 1 more · For: Healthy Volunteers
Sites: Daytona Beach, Florida
Instituto Oncológico Dr RosellAcademic, hospital or other
NCT04772235 · 32 participants (planned) · Start Feb 11, 2022 · Primary completion Apr 2026
Drug: Repotrectinib; Osimertinib · For: Nsclc
Sites: Málaga, Spain; Palma, Spain; Barcelona, Spain · 4 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07223671 · 30 participants · Start Dec 31, 2025 · Primary completion Feb 19, 2026
Drug: Repotrectinib; Metformin and 5 more · For: Healthy Volunteers
Sites: Daytona Beach, Florida
Centre Hospitalier Intercommunal de Toulon La Seyne sur MerAcademic, hospital or other
NCT06552234 · 30 participants (planned) · Start Oct 1, 2024 · Primary completion Sep 2031
Drug: Repotrectinib · For: NSCLC Stage IV; NSCLC, Stage III
Sites: Aix-en-Provence, France; Marseille, France; Toulon, France · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness44
- death28
- nausea21
- off label use19
- neuropathy peripheral18
- fatigue13
- adverse event12
- pain12
- muscular weakness11
- paraesthesia10
- balance disorder9
- diarrhoea9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2024 | 100 |
| 2025 | 114 |
| 2026 | 58 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Augtyro (Repotrectinib)
2024 spending
$9.8M
Beneficiaries
150
461 claims
Per beneficiary
$65,193
$121.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $9,778,948 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, et al. · N Engl J Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
Barbato MI, Bradford D, Ren Y, et al. · Clin Cancer Res 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
Ahn BC, Kim YJ, Lee Y, et al. · JAMA Oncol 2026 · Multicenter Study, Clinical Trial, Phase II
- Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
Drilon A, Cho BC, Camidge DR, et al. · Oncologist 2026 · Clinical Trial, Phase I, Multicenter Study
- Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.
Aguilar A, Cobo M, Calles A, et al. · Lung Cancer 2026 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.
Besse B, Lin JJ, Bazhenova L, et al. · Nat Med 2026 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.